Monocentric retrospective study shows clinical outcomes of baricitinib, ritlecitinib, and upadacitinib in alopecia areata, indicating varying effectiveness.
The introduction of Janus kinase inhibitors has revolutionized the management of alopecia areata. We conducted a monocentric retrospective study aimed at comparing the clinical, trichoscopic, and safety outcomes of baricitinib, ritlecitinib, and upadacitinib in patients with moderate-to-severe alopecia areata.
No takes yet. Share an insight, caveat, or question.
Foggia et al. (2025) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: